Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
6 lessons
9mUBT251 is a once-weekly GLP-1, GIP and glucagon receptor agonist in development in China. Two phase 2 trials published in Cell Metabolism in October 2026. Here is what they measured, how to read the numbers, and why they can't be ranked against retatrutide.
8mRetatrutide is still the loudest metabolic signal in the room. The people who get the best result are the ones who track body composition, not just pounds lost.
9mRetatrutide changes the appetite game fast. The people who get the best result are the ones who keep protein, training, and waist measurements in view at the same time.
9mRetatrutide is forcing a better conversation about fat loss. The scale matters, but body composition, protein, and strength tell you whether the result will hold.
9mRetatrutide keeps stacking strong data, and the latest trial update sharpens the path toward an FDA submission. The bigger story is not just weight loss. It is how the triple-agonist profile may change what obesity medicine expects from a next-wave therapy.
7mDapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.
Also available at /blog for legacy links.